News
Lindis biotech presents encouraging data from bladder cancer trial
Lindis Biotech has announced positive data from all three dose groups from its ongoing Catunibla phase 1 trial. The objective of developing the drug candidate is to reduce the rate of radical bladder removal as well as to decrease recurrence and progression rates.